CompanyGraph
Duality Biotherapeutics, Inc.
9606 · HKEX · China
Price data from its 4ZB listing on FSX, quoted in EUR
dualitybiologics.comFinancials as of FY2025
What stands out
- Valued far above the size of its business
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $3.88B, above the global median of $1.15B
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Valued far above the size of its business
Financials view
Market Capitalization
30.41BHKD3.88B · vs all stocks (USD)
Revenue (TTM)
988.71MHKD126.08M · vs all stocks (USD)
Profit Margin
-170.82%vs Biotechnology peers
52-Week Change
-49.83%vs all stocks
Forward Annual Dividend Yield
0.00%vs all stocks
Market Capitalization
30.41BHKD3.88B · vs all stocks (USD)
Enterprise Value
13.08BHKD1.67B · vs all stocks (USD)
Forward P/E
-18.04xvs Biotechnology peers
Price to Sales (TTM)
16.54xvs Biotechnology peers
Price to Book (MRQ)
8.10xvs Biotechnology peers
Enterprise to Revenue
13.23xvs Biotechnology peers
Enterprise to EBITDA
-7.51xvs Biotechnology peers
Gross Margin
26.11%vs Biotechnology peers
Profit Margin
-170.82%vs Biotechnology peers
Operating Margin
-418.28%vs Biotechnology peers
Return on Assets (TTM)
-24.30%vs Biotechnology peers
Return on Equity (TTM)
-65.93%vs Biotechnology peers
Revenue (TTM)
988.71MHKD126.08M · vs all stocks (USD)
Revenue per Share (TTM)
9.42HKDUpdated Oct 24, 2026Quarterly Revenue Growth
-82.20%vs Biotechnology peers
Gross Profit (TTM)
-274.34MHKD-34.98M · vs all stocks (USD)
EBITDA (TTM)
-1.74BHKD-222.27M · vs all stocks (USD)
Net Income (TTM)
-1.69BHKD-215.37M · vs all stocks (USD)
Operating Cash Flow (TTM)
-961.42MHKD-122.60M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-200.19MHKD-25.53M · vs all stocks (USD)
Forward Annual Dividend Yield
0.00%vs all stocks
Trailing Annual Dividend Rate
0.00HKDUpdated Oct 24, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
EPS (Basic)
-29.47CNYFY2025 · Dec 31, 2025EPS (Diluted)
-29.47CNYFY2025 · Dec 31, 2025Operating Cash Flow
-2.31BCNYFY2025 · Dec 31, 2025Free Cash Flow
-2.32BCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
1.28BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-2.59BCNYFY2025 · Dec 31, 2025Stock-based Compensation
156.05MCNYFY2025 · Dec 31, 2025Other Non-cash Items
-98.10MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
33.84MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
189.83MCNYFY2025 · Dec 31, 2025Capital Expenditures
-11.50MCNYFY2025 · Dec 31, 2025Net Intangibles (CF)
-2.22MCNYFY2025 · Dec 31, 2025Purchase of Investments
-4.64BCNYFY2025 · Dec 31, 2025Sale of Investments
2.75BCNYFY2025 · Dec 31, 2025Other Investing Activity
-4.55MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-1.91BCNYFY2025 · Dec 31, 2025Net Short-term Debt Issuance
141.06MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
1.90BCNYFY2025 · Dec 31, 2025Shares Outstanding
89.42MSharesUpdated Oct 24, 2026Float Shares
51.01MSharesUpdated Oct 24, 2026% Held by Insiders
19.16%vs all stocks
% Held by Institutions
40.83%vs all stocks
Total Cash (MRQ)
3.57BHKD455.52M · vs all stocks (USD)
Total Cash per Share (MRQ)
33.60HKDUpdated Oct 24, 2026Total Debt (MRQ)
445.51MHKD56.81M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.2616xvs Biotechnology peers
Current Ratio (MRQ)
1.99xvs Biotechnology peers
Book Value per Share (MRQ)
18.83HKDUpdated Oct 24, 2026Total Assets
3.89BCNY583.62M · vs all stocks (USD)
Total Current Assets
3.83BCNYFY2025 · Dec 31, 2025Total Liabilities
1.47BCNYFY2025 · Dec 31, 2025Total Non-current Assets
58.73MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
414.35MCNYFY2025 · Dec 31, 2025Total Current Liabilities
1.05BCNYFY2025 · Dec 31, 2025Cash
3.27BCNYFY2025 · Dec 31, 2025Cash Equivalents
-2.00BCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
1.28BCNYFY2025 · Dec 31, 2025Other Short-term Investments
2.10BCNYFY2025 · Dec 31, 2025Accounts Receivable
277.92MCNYFY2025 · Dec 31, 2025Accounts Payable
761.94MCNYFY2025 · Dec 31, 2025Short-term Debt
145.87MCNYFY2025 · Dec 31, 2025Long-term Debt
3.91MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
169.53MCNYFY2025 · Dec 31, 2025Common Stock (Book)
58.00KCNYFY2025 · Dec 31, 2025Retained Earnings
-4.85BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
2.43BCNY363.81M · vs all stocks (USD)
52-Week Low
145.50HKDUpdated Oct 24, 202652-Week High
376.80HKDUpdated Oct 24, 202652-Week Change
-49.83%vs all stocks
50-Day MA
187.52HKDUpdated Oct 24, 2026200-Day MA
248.20HKDUpdated Oct 24, 2026Avg 10-Day Volume
1.04MSharesUpdated Oct 24, 2026Avg 30-Day Volume
854.83KSharesUpdated Oct 24, 2026Diluted EPS (TTM)
-0.3400HKDUpdated Oct 24, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Valued far above the size of its businessSignificant
Price-to-Sales: 16.54Revenue Growth YoY: -0.82
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $3.88B, above the global median of $1.15BNotable
Market cap (USD): 3,877,593,054.382Global Median: 1,150,342,212.262
Companies that share the same coordination system — how they create, deliver, or capture value.
Celcuity Inc.
Tier 1ProductionApproval-Gated PipelineRule
Catalyst Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Jiangsu Yuyue Medical Equipment & Supply Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Mgi Tech Co Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shijiazhuang Yiling Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Relay Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Amylyx Pharmaceuticals, Inc. Common Stock
Tier 1ProductionApproval-Gated PipelineRule
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited
Tier 1ProductionApproval-Gated PipelineRule
Hanmi Pharm Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Livzon Pharmaceutical Group Inc.
Tier 1ProductionApproval-Gated PipelineRule